The Benchmarking Study was designed to measure policy, implementation, and coverage milestones along the licensure-to-adoption pathway in 73 Gavi-eligible countries. The study collected dates and analyzed milestones across six vaccine-preventable diseases (VPDs) and their corresponding prequalified vaccines (pentavalent vaccine, PCV, RVV, HPV vaccine, IPV, MenA vaccine).Read More >
What We DoThe International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Our Approach Blends
- Rigorous science
- Productive partnership
- Clear communication
- Capacity building and training
Our Practice Areas
Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.
Coverage & Equity
To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.
Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.
To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.
Economics & Finance
To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.
To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.
To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.
As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.
To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.
Following the recommendation of the Expert Advisory meeting in February 2017 to perform a contingent valuation study, the team reviewed the literature and participated in high-level discussions with experts in this field to make a preliminary assessment of how much it would take to pilot various willingness to pay/contingent valuation methodsRead More >
The DOVE III team has developed a suite of models that demonstrate the value of vaccines and assess progress of national immunization programs against the Global Vaccine Action Plan. We enable donors and international bodies to make informed decisions on regional and global vaccine investments and strategies.Read More >
The Decade of Vaccine Economics (DOVE) IV generates evidence on the economic impact of vaccination by building upon previously developed DOVE models and gathering primary data on the cost of illness averted due to vaccine preventable diseases in two low- or middle-income countries.Read More >